More and more Americans are turning to GLP-1 injections to lose weight. FOX 7 Austin's Rebecca Thomas spoke to an Austin ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

More and more Americans are turning to GLP-1 injections to lose weight. FOX 7 Austin's Rebecca Thomas spoke to an Austin physician to discuss.

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based medical technology enterprise, was recently approved for market by China's ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...

Lixisenatide requires daily injections, while newer GLP-1-targeting drugs like Ozempic and Wegovy, as well as Eli Lilly’s tirzepatide-based Mounjaro and Zepbound, only need to be given once a ...

Yorvipath cuts the number of daily injections needed to treat hypoparathyroidism ... allowing it to tap into the burgeoning market for GLP-1 therapies for diabetes, obesity, and other associated ...